Top in rheumatology: Autoimmunity awareness, Ehlers-Danlos syndrome
Click Here to Manage Email Alerts
In a recent editorial, Nicole Bundy, MD, medical director at Mymee Inc., said that celebrities do a good job raising awareness of autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and lupus, but more discussion is needed.
In particular, she said there is a need to acknowledge the important role of diet, lifestyle and environment in the onset and course of autoimmune disease. It was the top story in rheumatology last week.
Another top story was about the lack of treatment options for patients with Ehlers-Danlos syndrome. Healio spoke with medical geneticist David R. Deyle, MD, about the disease and the FDA’s orphan drug designation to enzastaurin (AR101, Aytu Biopharma) for the treatment of Ehlers-Danlos syndrome.
Read these and more top stories in rheumatology below:
'We must do better': Celebrity cases pull autoimmunity epidemic into limelight
Every so often, autoimmunity hits the mainstream media. Usually this happens when a celebrity bravely uses their place in the limelight to raise awareness by publicly sharing news about their diagnosis. Read more.
'It can be really bad': Vascular Ehlers-Danlos syndrome treatment options remain limited
Ehlers-Danlos syndrome can be a devastating disease in patients who are severely affected — a situation made worse by the current scarcity of treatment options. Read more.
Heart healthy, Mediterranean diets reduce gout risk in women; Western diet increases risk
High adherence to healthy diet options found within the USDA’s 2020-2025 Dietary Guidelines for Americans, including the heart-healthy DASH or the Mediterranean diet, significantly reduces the risk for gout in women, according to data. Read more.
'STAR' treatment: Personalized referrals improve chronic pain after total knee replacement
A personalized referral system dubbed Support and Treatment After Replacement, or STAR, is cost effective and improves chronic pain after total knee replacement over a 1-year period, according to data published in The Lancet Rheumatology. Read more.
Anifrolumab reduces lupus disease activity across musculoskeletal, mucocutaneous domains
Anifrolumab improves systemic lupus erythematosus disease activity across musculoskeletal, mucocutaneous and immunological domains, according to a post-hoc analysis of TULIP-1 and TULIP-2 data published in The Lancet Rheumatology. Read more.